Radioligand Therapy Market is expected to reach a US$13 bn market at a growth rate of ~5% by 2030

BRUSSELS - Jan. 23, 2024 - PRLog -- Radioligand therapy (https://meditechinsights.com/radioligand-therapy-market/) is a type of precision nuclear medicine used to treat advanced cancer patients. Radioligand therapy, also known as radionuclide or radiopharmaceutical therapy, is a type of cancer treatment in which radiation is delivered directly to cancer cells.

A radioisotope, which produces radiation that kills cells, and a targeted ligand, a chemical that binds to particular markers on cancer cells, are the two main components of radioligand treatments.

A Clinical Trial Advancement for Therapeutic Radiopharmaceutical Pipelines Will Drive Radioligand Therapy Market Growth

In recent years, oncology research has made great strides. Radioligand treatments have the potential to change oncology's standard of care. Clinical studies are essential for determining the efficacy and safety of therapeutic radiopharmaceuticals.

• In December 2023, Lantheus Holdings, Inc. and POINT Biopharma Global Inc. announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002.
• In May 2023, RadioMedix and Orano Med announced that the last patient had been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE (AlphaMedix).

Radioligand Therapy's Emerging Applications in Neuroendocrine Neoplasms, Prostate Cancer, and Non-cancerous Conditions Increase Radioligand Therapy Market Demand

Cancer care has advanced in many areas, including advancements in treatment and therapy, but for many patients, effective therapeutic choices remain unavailable. The most recent radioligand applications focus on NETs and bone metastases in mCRPC, with research in many other cancer and non-cancer disorders underway. Radioligand treatment directs radiation to certain types of cells and is progressively developing as an important pillar in cancer care. Among the new uses of radioligand treatment are:

North America controls the majority of the Global Radioligand Therapy market

North America has emerged as the global leader in radioligand treatment. The area is seeing significant market expansion, which is being driven by rigorous laws controlling the healthcare and pharmaceutical industries.

Radioligand Market - Competitive Landscape

The top market players in the radioligand therapy market include Novartis International AG, POINT Biopharma Global Inc., Fusion Pharma, Orano Med, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings, Inc., Bayer AG, Eli Lilly, Molecular Partners, ITM Isotope Technologies Munich SE, Curium Pharma, Precirix, and Radio Medix, among others.

Radioligand treatment is a technological advancement from imaging to therapy. The market is expected to expand further as pharmaceutical companies increase their investments in the development and commercialization of radioligand therapies, as radioligand therapy applications expand, imaging technologies advance, and players pursue aggressive organic and inorganic growth strategies.

Get Detailed Insights on the Radioligand Therapy Market @ https://meditechinsights.com/radioligand-therapy-market/